StocksMedium•16 November 2026•
1 min read
Neumora Therapeutics Reports Narrower-Than-Expected Q3 Loss
Key Facts
1Neumora Therapeutics reported a GAAP EPS loss of $0.18, beating analyst estimates by $0.02.
Neumora Therapeutics reported a GAAP loss per share of $0.18 for the third quarter of 2026. Seeking Alpha reported that these results beat analyst estimates by $0.02, as the company posted a narrower loss than the consensus forecast.
The company stated it held $85.7 million in cash and cash equivalents as of September 30, 2026, though it did not provide updated financial runway guidance. NMRA closed at $0.4289 on November 13, 2026.